Catalyst Pharmaceuticals: Undervalued Cash Flow Generator With High Probability Of Outperformance
Photo by Geber86/E+ via Getty Images
Catalyst Pharmaceuticals (NASDAQ:CPRX) is a small cap biopharmaceutical company with a highly profitable ultra-orphan drug Firdapse. We believe that the threat of Ruzurgi has been priced into their Catalyst’s stock price and further development in their lawsuit with Jacobus might provide surprises on the upside. Additionally, the company continues to generate high margins and free cash flow, with a fortress balance sheet to pursue R&D and M&A. The latest earnings…
